Cargando…

Anti-Inflammatory Effect of Vitamin D via Suppression of YKL-40 Production: One of the Possible Mechanisms for Cardiovascular Protection

Detalles Bibliográficos
Autor principal:	Kim, Hack-Lyoung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Cardiology 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932223/ https://www.ncbi.nlm.nih.gov/pubmed/36792560 http://dx.doi.org/10.4070/kcj.2023.0016

Ejemplares similares

YKL-40 as a possible marker of neutrophilic asthma
por: Specjalski, Krzysztof, et al.
Publicado: (2023)

YKL-40 - an emerging biomarker in cardiovascular disease and diabetes
por: Rathcke, Camilla N, et al.
Publicado: (2009)

Effect of Vitamin D on YKL-40: Rat Hypercholesterolemia Model
por: Kocabas, Rahim
Publicado: (2023)

Serum YKL-40 and colorectal cancer
por: Cintin, C, et al.
Publicado: (1999)

YKL-40 correlates with the phenotype of asthma
por: Specjalski, Krzysztof, et al.
Publicado: (2015)

Chitinase-like protein YKL-40 correlates with inflammatory phenotypes, anti-asthma responsiveness and future exacerbations
por: Liu, Lei, et al.
Publicado: (2019)

Systemic Immune Modulation in Gliomas: Prognostic Value of Plasma IL-6, YKL-40, and Genetic Variation in YKL-40
por: Holst, Camilla Bjørnbak, et al.
Publicado: (2020)

YKL-40 and its complex association with metabolic syndrome, obesity, and cardiovascular disease
por: Schernthaner, Gerit-Holger, et al.
Publicado: (2016)

YKL-40 Protein Correlates with the Phenotype of Asthma
por: Specjalski, Krzysztof, et al.
Publicado: (2015)

Plasma YKL-40 in the spectrum of neurodegenerative dementia
por: Villar-Piqué, Anna, et al.
Publicado: (2019)

The inflammatory biomarker YKL-40 decreases stepwise after exercise stress test
por: Dam Mygind, Naja, et al.
Publicado: (2016)

YKL-40 as a Potential Biomarker and a Possible Target in Therapeutic Strategies of Alzheimer’s Disease
por: Muszyński, Paweł, et al.
Publicado: (2017)

YKL-40 serum levels are predicted by inflammatory state, age and diagnosis of idiopathic inflammatory myopathies
por: Vázquez-Del Mercado, Mónica, et al.
Publicado: (2023)

Serum YKL-40 Levels in Patients with Gastric Cancer
por: Itik, Veyis, et al.
Publicado: (2011)

YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias
por: Llorens, Franc, et al.
Publicado: (2017)

YKL-40 and the Cellular Metabolic Profile in Parkinson’s Disease
por: Gevezova, Maria, et al.
Publicado: (2023)

Prognostic performance of serum YKL-40 for one-year clinical outcomes in acute ischemic stroke
por: Shi, Guomei, et al.
Publicado: (2023)

Elevation of YKL-40 in the CSF of Anti-NMDAR Encephalitis Patients Is Associated With Poor Prognosis
por: Chen, Jinyu, et al.
Publicado: (2018)

YKL-40, a secreted glycoprotein, promotes tumor angiogenesis
por: Shao, Rong, et al.
Publicado: (2009)

YKL-40 acts as an angiogenic factor to promote tumor angiogenesis
por: Shao, Rong
Publicado: (2013)

Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularization
por: Shao, Rong, et al.
Publicado: (2015)

Cerebrospinal fluid neurogranin and YKL‐40 as biomarkers of Alzheimer's disease
por: Janelidze, Shorena, et al.
Publicado: (2015)

Prognosis and Reclassification by YKL‐40 in Stable Coronary Artery Disease
por: Schroder, Jakob, et al.
Publicado: (2020)

The new marker YKL-40, a molecule related to inflammation, is associated with cardiovascular events in stable haemodialysis patients
por: Vega, Almudena, et al.
Publicado: (2019)

Prognostic implications of immunohistochemically detected YKL-40 expression in breast cancer
por: Kim, Steve H, et al.
Publicado: (2007)

YKL-40 levels are independently associated with albuminuria in type 2 diabetes
por: Røndbjerg, Anne K, et al.
Publicado: (2011)

YKL-40 tissue expression and plasma levels in patients with ovarian cancer
por: Høgdall, Estrid VS, et al.
Publicado: (2009)

Increased immunohistochemical expression of YKL-40 in the spleen of patients with portal hypertension
por: Wang, Dong, et al.
Publicado: (2012)

Unveiling YKL-40, from Serum Marker to Target Therapy in Glioblastoma
por: Iwamoto, Fabio M., et al.
Publicado: (2014)

CTX-II and YKL-40 in early diagnosis and treatment evaluation of osteoarthritis
por: Wang, Pengkun, et al.
Publicado: (2019)

Serum YKL-40 levels and disease characteristics in patients with rheumatoid arthritis
por: Jafari-Nakhjavani, Mohammad Reza, et al.
Publicado: (2019)

Circulatory YKL-40 & NLR: Underestimated Prognostic Indicators in Diffuse Glioma
por: Gandhi, Puneet, et al.
Publicado: (2018)

Serum YKL-40 Levels Are Associated with the Atherogenic Index of Plasma in Children
por: Kwon, Yoowon, et al.
Publicado: (2020)

YKL-40 Is Associated With Ultrasound-Determined Carotid Atherosclerotic Plaque Instability
por: Wang, Yu, et al.
Publicado: (2021)

Prognostic Impact of YKL-40 Immunohistochemical Expression in Patients with Colorectal Cancer
por: Oh, Il Hwan, et al.
Publicado: (2021)

Perspective: targeting VEGF-A and YKL-40 in glioblastoma – matter matters
por: Holst, Camilla Bjørnbak, et al.
Publicado: (2021)

YKL-40 as a Potential Biomarker for the Differential Diagnosis of Alzheimer’s Disease
por: Mavroudis, Ioannis, et al.
Publicado: (2021)

The role of YKL-40 in the pathogenesis of autoimmune diseases: a comprehensive review
por: Tizaoui, Kalthoum, et al.
Publicado: (2022)

Conserved YKL-40 changes in mice and humans after postoperative delirium
por: David-Bercholz, Jennifer, et al.
Publicado: (2022)

YKL-40 is a Protective Biomarker for Fatty Liver in World Trade Center Particulate Matter-Exposed Firefighters
por: Cho, Soo Jung, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_qnumvcolom1us7daajvvlh1m10